Dataset Information
Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
Ontology highlight
ABSTRACT: Context
Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in type 2 diabetes and obesity. The interplay between ambient free fatty acids (FFAs) and GLP-1 remains unclear. Acipimox suppresses adipose tissue lipolysis via activation of the PUMA-G (also known as HCA2 and GPR109a) receptor.Objective
To investigate whether lowering of serum FFA level with acipimox affects GLP-1 secretion.Design
Two randomized crossover studies were performed in human subjects. Rat intestine was perfused intra-arterially and intraluminally, and l-cells were incubated with acipimox.Participants
The participants were healthy overweight subjects and hypopituitary adult patients.Interventions
The overweight participants received acipimox 250 mg 60 minutes before an oral glucose test. The hypopituitary patients received acipimox 250 mg 12, 9, and 2 hours before and during the metabolic study day, when they were studied in the basal state and during a hyperinsulinemic euglycemic clamp.Results
Acipimox suppressed FFA but did not affect insulin in the clinical trials. In overweight subjects, the GLP-1 increase after the oral glucose tolerance test (area under the curve) was more than doubled [4119 ± 607 pmol/L × min (Acipimox) vs 1973 ± 375 pmol/L × min (control), P = 0.004]. In hypopituitary patients, acipimox improved insulin sensitivity (4.7 ± 0.8 mg glucose/kg/min (Acipimox) vs 3.1 ± 0.5 mg glucose/kg/min (control), P = 0.005], and GLP-1 concentrations increased ~40%. An inverse correlation between FFA and GLP-1 concentrations existed in both trials. In rat intestine, acipimox did not affect GLP-1 secretion, and l-cells did not consistently express the putative receptor for acipimox.Conclusions
Acipimox treatment increases systemic GLP-1 levels in both obese subjects and hypopituitary patients. Our in vitro data indicate that the underlying mechanisms are indirect.
SUBMITTER: Vestergaard ET
PROVIDER: S-EPMC7212086 | biostudies-literature | 2019 Jul
REPOSITORIES: biostudies-literature
Publications
Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
The Journal of clinical endocrinology and metabolism 20190701 7
<h4>Context</h4>Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in type 2 diabetes and obesity. The interplay between ambient free fatty acids (FFAs) and GLP-1 remains unclear. Acipimox suppresses adipose tissue lipolysis via activation of the PUMA-G (also known as HCA2 and GPR109a) receptor.<h4>Objective</h4>To investigate whether lowering of serum FFA level with acipimox affects GLP-1 secretion.<h4>Design</h4>Two randomized crossover studies were performed in human ...[more]